Am­gen, Sanofi and Mer­ck an­nounce a string of deals at #JPM17; Mc­Do­nough out at So­bi

• Am­gen has tied the knot with Ger­many’s Im­mat­ics, pay­ing $30 mil­lion up­front and of­fer­ing hun­dreds of mil­lions more in pos­si­ble mile­stones for the de­vel­op­ment of bis­pe­cif­ic T cell-en­gag­ing ther­a­peu­tics for a range of can­cers.

• Just weeks af­ter Im­muNext signed Roche up as a part­ner, Sanofi has stepped on board to part­ner on a pre­clin­i­cal CD40L an­ti­body for au­toim­mune dis­ease that has po­ten­tial in treat­ing mul­ti­ple scle­ro­sis and lu­pus. The deal is worth a po­ten­tial $500 mil­lion, though it like­ly starts out on the small side.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.